We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Pharmacogenetics
- Pharmacogenomics
- Pharmacogenetics: brief history
- Specific examples to be considered
- Debrisoquine (CYP2D6) polymorphism
- Debrisoquine polymorphism: studies on phenotype
- Cytochromes P450
- Molecular basis of CYP2D6 polymorphism
- Poor metabolism and CYP2D6 polymorphisms
- Copy number variants in CYP2D6
- Number of CYP2D6 genes and nortryptiline
- Tamoxifen and CYP2D6
- CYP2D6 and codeine
- Ultrarapid metabolizers and codeine
- CYP2C9
- Functional effect of CYP2C9 alleles
- Warfarin
- Vitamin K cycle
- CYP2C9 genotypes and warfarin
- Warfarin dose requirement
- Vitamin K epoxide reductase
- VKORC1 polymorphisms (1)
- VKORC1 polymorphisms (2)
- CYP2C9/VKORC1 genotype warfarin dose
- Warfarin and pharmacogenetics
- Association study on warfarin dose requirement
- Methyltransferases
- Thiopurine S-methyltransferase (TPMT)
- TPMT polymorphism (1)
- TPMT polymorphism (2)
- Idiosyncratic adverse drug reactions
- Simvastatin myopathy
- Flucloxacillin-induced liver injury
- Summary
- References
Topics Covered
- Definition and history
- CYP2D6 polymorphism
- Pharmacogenetics of warfarin
- Thiopurine methyltransferase
- Genetics susceptibility to adverse drug reactions
Links
Series:
Categories:
Talk Citation
Daly, A. (2009, December 28). Pharmacogenetics [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 9, 2024, from https://doi.org/10.69645/CZYP1010.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Ann Daly has no commercial/financial relationships to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Ann Daly from
Newcastle University,
and I want to
introduce you today
to the topic of
pharmacogenetics.
0:10
What is pharmacogenetics?
It's the study of unusual
responses to drugs
and other foreign compounds
that have a hereditary basis.
This is a term that
was first used in
the 1950s by scientists
called Vogel and Motulsky.
0:28
More recently in the 1990s,
the term pharmacogenomics
has emerged.
Pharmacogenomics is
the individualization
of drug therapy using
genomic information.
Now that may involve using
existing well known drugs
or using genomic information
to develop new ones.
Pharmacogenetics is a sub
specialty of pharmacogenomics.
But there is considerable
overlap between
these two subject areas
and for the purposes
of this presentation,
I'm not going to
differentiate between them.
1:08
This slide explains a little bit
about the history of
pharmacogenetics.
The first real
pharmacogenetic experiment
was performed in 1932
when Snyder showed
that inability to
taste something called
phenylthiocarbamide,
which has a bitter taste,
was genetically inherited.
Some modern drugs have
a similar structure to
phenylthiocarbamide.
In the 1950s,
when the term pharmacogenetics
was actually
starting to be used,
genetic polymorphisms
in at least three genes
encoding glucose
6-phosphate dehydrogenase,
butyrylcholinesterase and
acetylation were described.
In the 1970s and 1980s,
detailed studies showed
the existence of
widespread polymorphism
in the cytochromes P450.